Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Post by C10H12N2on Jan 28, 2022 4:27pm
173 Views
Post# 34373036

BearInTheWoods Continues Psychopath Attack On AGN @ CEO.CA

BearInTheWoods Continues Psychopath Attack On AGN @ CEO.CA 




Bear claims Algernon added salt to it;'s approved patent for Ifenprodil - False


Bear has made the psychopath argument that Algernon has zero patents - False


Bear now changes course about not having patents to suggest any patent by Algernon is worthless - False


Bear continues to not understand Ifenprodil sold in Japan is not the same as Ifenprodil not being sold outside of Japan for FDA approved use - True


Bear believes management issuing itself stock options is a nefarious act - False


Bear believes a consolidation of share to uplist to Nasdaq is a bad idea versus staying on the CSE - False


Bear believes the 1 hour Q&A put on by the CEO recently was not a positive and meaningful engagement with shareholders - False


Bear keeps going back and forth about Algernon having conducted 3 failed Phase 2 clinical trials - False


Bear believes paid advertising by a company with no revenues is bad business - False


Bear has no clue about DMt and the psychedelic space that he shallowly tries to pontificate about like most everything else about Algernon - True


Bear will look directly at a news release and pull something out of it that does not exist on paper or anywhere else but his pathological liar brain - True


Bear has the audacity to take just about every bad thing that was expressed by other posters about Algernon and package them up as his due diligence that he warned everyone about at Stockhouse AGN - False


Bear will continue to make sh!t up here there and anywhere else he takes a sh!t with his fingers on a keyboard - True


Bear does not care about the truth - True


if anyone truly cares about what Bear thinks you too need your head examined - True


Algernon is headed to Nasdaq in Q1 2022 - True


Algernon has filed a plethora of patents to protect it's properties on a global scale - Tur


Algernon;'s best days are ahead - True


Algernon's share price is currently suppressed - Ture


Algernon has 3 if not 4 clinical trials happening in 2022 - True]\


Algernon has 2 of the world's top psychedelic names on the team - True


Algernon remains a relatively unknown company until it gets the free ink exposure it deserves once uplisted to Nasdaq - true


Algernon will be mentioned among the likes of GH Research, MindMed, Compass Pathways and a handful of other gtrue movers in the multibillion dollar psychedelic space - True


Psychedelics are predicted by experts to shift the global paradigm for neuroscience - True


Algernon has just as good a shot at winning with it's pipeline as anyone else out there at Phase 1 and Phase 2 of the clinical trial process - True


It only gets better from here for Algernon regardless to the market meltdown - True


Good luck with your play here as Algernon has no competing elements other than AGN shareholders like facts over fiction when it comes to calling out another company - True

 


<< Previous
Bullboard Posts
Next >>